Today, the Food and Drug Administration (FDA) announced the approval of mavacamten, a new drug shown to provide relief to obstructive hypertrophic cardiomyopathy patients experiencing shortness of breath.

news, journals and articles from all over the world.
Today, the Food and Drug Administration (FDA) announced the approval of mavacamten, a new drug shown to provide relief to obstructive hypertrophic cardiomyopathy patients experiencing shortness of breath.
Cardiologists and cardiothoracic surgeons from the Smidt Heart Institute at Cedars-Sinai are available to discuss the latest advances in research, clinical care, transcatheter procedures and cardiothoracic surgery throughout the International Society for Heart and Lung Transplantation (ISHLT) Scientific Sessions 2022 and Heart Rhythm 2022.